prostate cancer

Pharma

FDA approves use of Bayer's Nubeqa in all patients with mCSPC

Bayer has scored an important FDA label expansion for Nubeqa, which now can be used by all patients with metastatic castration-sensitive prostate cancer.

Kevin Dunleavy Jun 4, 2025 11:38am

J&J PARP path unclear in castration-sensitive prostate cancer subset

Jun 3, 2025 8:00am

AstraZeneca, Zero Prostate Cancer rev up early detection push

May 23, 2025 11:24am

FDA advisors unanimously reject Pfizer's Talzenna expansion bid

May 22, 2025 10:20am

Fierce Healthcare

Biden diagnosed with 'aggressive' prostate cancer

May 19, 2025 11:40am

AstraZeneca's Truqap falls short in another phase 3 trial

Apr 29, 2025 3:26pm